Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications A Propensity Score-Matched Outcome Study

作者：Austin David; Oldroyd Keith G; McConnachie Alex; Slack Rachel; Eteiba Hany; Flapan Andrew D; Jennings Kevin P; Northcote Robin J; Pell Alastair C H; Starkey Ian R; Pell Jill P^*

来源：Circulation: Cardiovascular Interventions , 2008, 1(1): 45-52.

DOI：10.1161/CIRCINTERVENTIONS.108.769042

• angioplasty
• coronary disease
• stents
• myocardial infarction
• stents, drug-eluting

Background-The US Food and Drug Administration recently concluded that data on off-label drug-eluting stent (DES) safety are limited. However, in actual clinical practice, DES are often used for off-label indications, and observational studies demonstrate that complications are higher when compared with on-label use. We aimed to determine whether clinical outcomes differ after DES and bare-metal stent implantation in a patient cohort defined by DES off-label indications.
Methods and Results-We used the national revascularization registry in Scotland to identify patients who underwent coronary stenting for an off-label indication between January 2003 and September 2005. Individual-level linkage to comprehensive national admission and death databases was used to ascertain the end points of death, myocardial infarction, and target-vessel revascularization. We calculated propensity scores on the basis of clinical, demographic, and angiographic variables and matched DES to bare-metal stents on a 1:1 basis. The final study population consisted of 1642 patients, well matched for important covariables at baseline. Event-free survival was calculated over 24 months with the Kaplan-Meier method. All-cause death was more common after bare-metal stent implantation during follow-up (7.7% versus 6.6%; hazard ratio 0.63; 95% confidence interval, 0.40 to 0.99; P=0.04). No difference in the rates of myocardial infarction were noted (7.3% versus 7.5%; hazard ratio 1.02; 95% confidence interval, 0.69 to 1.54; P=0.92). Target-vessel revascularization was reduced in patients treated with DES (13.9% versus 10.7%; hazard ratio 0.67; 95% confidence interval, 0.49 to 0.93; P=0.02).
Conclusions-At 24 months, patients treated with DES for off-label indications had lower rates of death and target-vessel revascularization and similar rates of myocardial infarction, as compared with patients treated with bare-metal stents. (Circ Cardiovasc Intervent. 2008;1:45-52.)

• 出版日期2008-8